Bristol Myers Squibb Says alzheimer’s is the biggest market for new schizophrenia drug

Bristol Myers Squibb Believes Alzheimer’s is the largest market for its Newly Approved schizophrenia drug, Cobenfy.

In an interview, Company Executives Said Each Treatment Use. Ion, Bipolar Disease, and Autism. But alzheimer’s is the “really large market here,” Bristol Myrs Squibb Cfo David Elkins Told CNBC on TuesDay at the JPMorgan Health Care CON FRANCECE in San Francsco.

There are nearly 6 Million Patients in the Us With Alzheimer’sAnd Around Half of Them Have Psychosis, or Symptoms Such as Hallucines and Delusions, Elkins Said. Cobenfy even could be the first drug specifically approved for alzheimer’s-Related psychosis, Said Chief CommercializationOfficer Adam Lenkowsky.

Atypical antipsychotics – Medication used to treat a range of psychiatric disorders – are often used to treat psychosis in alzheimer’s patients even thoughts who they are not approved for that purpose. But thats treatments can increase the risk of death, and cobenfy does not, according to Bristol Myers Squibb.

Meanwhile, Alzheimer’s Agitation, A Symptom That Can Cause a Patient to Feel Restless and Word, is estimated to affect Around 60% to 70% of Patients with the Disease, According to 70% of Patients With the Disease Some Studies,

Bristol myers Squibb on Monday said it plans to release initial late-stage trial data for cobenfy in alzheimer’s-Reimer’s-Related Psychosis Treatment during the Latter Part of the year, which is expected. The company also expects to start phase three trials in alzheimer’s agitation, alzheimer’s cognition and bipolar disorder in 2025, while study in autism will begin in 2026.

JPMorgan Analyst Chris Schott Expects Cobenfy Sales to Reach About $ 5 Billion by 2030, with a peak sales potential in the $ 10 billion range mullion range Multiple Treatment uses, ACCORDING to A. That is a huge boy to Bristol myers squibb as it faces pressure to offset the potential losss of revealed from top-with-with-with-with-selling treatments that will see their patents expire.

It’s a full-circle moment for cobenf, which is the first novel type of treatment for the roughly 3 million us adults with schizophrenia in decades after it won app The Drug Comes from Bristol Myrs Squibb’s whopping $ 14 billion acquisition of biotech company karuna therapeutics At the end of 2023.

But the drug’s roots are in treating alzheimer’s.

Eli Lilly Originally Tested One Part of the Drug – Xanomeline – In the 1990s to Reduce Cognitive Declining Before Shelving It Due to Severe Side Effects Such as Nausea, Vomiting, Vomiting, Diarrhea and Constitution. Xanomeline activates certain so-called muscarinic receptors in the brain to decrease dopamine activity without causing the side effects associateed with antilchotics.

Andrew Miller, Founder and Former President of Research and Development of Karuna Therapeutics and Now an Advisor to Bristol Myers Squibb, Saw Xanomeline’s Potanical in Neuroscience and Theorized Combining Xanomeline Conded Existing Medication – Trospium – to reduce those side effects. He went on to launch karuna to develop the combination as a schizophrenia treatment.

Other Breakthrough treatments For Alzheimer’s recently entered the market, Including Biogen and Eisai ‘s leqambi and Eli lilly‘S Kisunla. Thos treatment work in part by clearing toxic plaques in the brain called amyloid, a hallmark of alzheimer’s, to slow the decline in memory and thinking in the earliest stages in the earliest stages of alzheimer ‘

But as People Progress through their disease, they experience symptoms such as psychosis and agitation, bristol myers Squibb’s elkins said.

“That’s where cobenfy fits it,” He said. “If you can get rid of the psychosis, the agitation, people’s cognition improves. Just imagine for the caregivers and health-caree system, how impactable this Drug COUG COLLD BES S really exciting when you think about It in that context. “